Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

AbbVie reports topline results from phase III study of upadacitinib

Dec. 21, 2017

Fresenius submits first biosimilar MAA to EMA

Dec. 19, 2017

Izana Bioscience launches, obtains rights to Takeda's namilumab for ankylosing spondylitis

Dec. 18, 2017

pSivida announces phase I data on sustained-release implant for osteoarthritis of the knee

Dec. 15, 2017

Phase IIb study of bimekizumab in ankylosing spondylitis meets primary objective

Dec. 15, 2017

FDA approves Xeljanz and Xeljanz XR for psoriatic arthritis

Dec. 15, 2017

Corbus Pharmaceuticals initiates phase III RESOLVE-1 trial testing anabasum

Dec. 15, 2017

FDA approves Pfizer's infliximab biosimilar Ixifi

Dec. 14, 2017

Phase III data show efficacy of LMWF-5A in severe knee osteoarthritis

Dec. 7, 2017

Glenmark Pharmaceuticals identifies new nuclear receptor ROR-gamma antagonists

Dec. 5, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...